Discontinuance of Immunosuprression in Renal Transplant Patients
Overview
Authors
Affiliations
Immunosuppressive therapy was discontinued in six patients for an average of 27 months. In these six patients, only two rejections have occurred. A survey of other transplant centers showed that in such patients rejection was often delayed weeks or months after therapy was stopped. Once immunosuppressive therapy has been stopped, for whatever reason, and rejection has not occurred, consideration should be given to not resuming therapy unless signs of rejection appear.
Regulatory B Cells in Solid Organ Transplantation: From Immune Monitoring to Immunotherapy.
Elias C, Chen C, Cherukuri A Transplantation. 2023; 108(5):1080-1089.
PMID: 37779239 PMC: 10985051. DOI: 10.1097/TP.0000000000004798.
Regulatory B cells: TIM-1, transplant tolerance, and rejection.
Cherukuri A, Mohib K, Rothstein D Immunol Rev. 2021; 299(1):31-44.
PMID: 33484008 PMC: 7968891. DOI: 10.1111/imr.12933.
Validation Study of an Operational Tolerance Signature in Korean Kidney Transplant Recipients.
Lee Y, Seo J, Kim Y, Moon J, Kim J, Jeong K Immune Netw. 2018; 18(5):e36.
PMID: 30402331 PMC: 6215901. DOI: 10.4110/in.2018.18.e36.
Newell K, Adams A, Turka L Hum Immunol. 2018; 79(5):380-387.
PMID: 29448053 PMC: 5924709. DOI: 10.1016/j.humimm.2018.02.007.
Operational tolerance in kidney transplantation and associated biomarkers.
Massart A, Ghisdal L, Abramowicz M, Abramowicz D Clin Exp Immunol. 2017; 189(2):138-157.
PMID: 28449211 PMC: 5508347. DOI: 10.1111/cei.12981.